Shanghai Shyndec shareholders approve director election, revised fund management

Shanghai Shyndec Pharmaceutical announced the resolutions from its second extraordinary general meeting of shareholders for 2025, held on September 15, 2025. Key approvals included the election of a director and the revision of the "Management Measures for the Use of Raised Funds." A total of 422 shareholders, representing 57.6129% of the company's voting shares, participated in the meeting.

The election of the director passed with 99.8439% of votes in favor, while the revised "Management Measures for the Use of Raised Funds" was approved with 99.0341% of votes. Beijing Zhong Lun (Shanghai) Law Firm confirmed that the meeting procedures complied with relevant laws and regulations, and the resolutions passed were legally effective.

The updated "Management Measures for the Use of Raised Funds" aims to enhance the management and efficient use of funds obtained through equity financing, ensuring compliance with national industrial policies and supporting the company's sustainable development. The revised policy mandates strict approval procedures for fund use, prohibits certain financial investments, and outlines detailed rules for temporary cash management and changes in investment projects.